Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HOUSE OPERATIONS/INTERGOVERNMENTAL SUBCMTE. AIDE ZELLER MOVES TO FDA

Executive Summary

HOUSE OPERATIONS/INTERGOVERNMENTAL SUBCMTE. AIDE ZELLER MOVES TO FDA April 19 to become special assistant to Deputy Commissioner for Policy Michael Taylor. Mitchell Zeller has worked as an aide to the House Government Operations/Intergovernmental Relations Subcommittee since late 1988 and is the last professional staff member who served under the late Chairman Rep. Weiss (D-N.Y.), who died last September and has been succeeded by Rep. Towns (D-N.Y.). The subcommittee was reorganized on Feb. 18 but will continue to oversee FDA operations. The new chairman is said to be interested in health care reform and in ensuring that user fee revenues are used to expedite the agency's drug approval process. However, in the wake of Weiss' death ("The Pink Sheet" Sept. 21, 1992, T&G-8) and the departure of his staff, the subcommittee is not likely to continue the kind of detailed scrutiny of FDA's scientific decisionmaking it conducted in the past. FDA issues Zeller worked on include FDA policy concessions to the Bush Administration's Council on Competitiveness, the label claims approved by FDA for the anti-arrhythmic drugs Tambocor and Enkaid, contamination problems with the nutritional supplement L- tryptophan, health claims for foods, and animal drug residues.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS022462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel